You are here

Article Text

Article menu
Download PDFPDF
Commentary
HBV infection and HCC: the ‘dangerous liaisons’

https://doi.org/10.1136/gutjnl-2017-315528

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors All the authors have contributed to the writing of the article.

    • Funding (Singapore Translational Research (STaR) Investigator Award (NMRC/STaR/013/2012).

    • Competing interests AB declares the following relationship with commercial entities developing therapeutics for HBV treatment. He collaborates and receives research support from Gilead Sciences to test the effect of HBV antigens on immune cell function. He acted as a consultant and served on the advisory boards of Gilead Sciences, MedImmune, Jansseen-Cilag, IONIS, Abivax, HUMABS BioMed. AB is also a cofounder of LION TCR pte. ltd. a biotech company developing T cell receptors for treatment of virus-related cancers and chronic viral diseases.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles